Ikena Oncology Inc

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

IMA$3.81-4.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Collaboration revenue	$—	$1,185	$—	$8,501
Operating expenses:
Research and development	6,818	14,654	26,295	45,378
General and administrative	4,777	6,034	16,084	16,632
Restructuring and other charges	812	—	4,077	—
Total operating expenses	12,407	20,688	46,456	62,010
Loss from operations	(12,407)	(19,503)	(46,456)	(53,509)
Other income (expense):
Investment income	1,771	2,162	5,805	4,840
Other income (expense)	412	(2)	640	(8)
Total other income, net	2,183	2,160	6,445	4,832
Loss before income taxes	(10,224)	(17,343)	(40,011)	(48,677)
Income tax expense	(10)	—	(99)	—
Net loss	$(10,234)	$(17,343)	$(40,110)	$(48,677)
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities	590	166	288	(290)
Total comprehensive loss	$(9,644)	$(17,177)	$(39,822)	$(48,967)
Net loss per share:
Net loss per share, basic and diluted	$(0.21)	$(0.40)	$(0.83)	$(1.23)
Weighted-average common shares outstanding, basic and diluted	48,258,111	43,437,844	48,258,111	39,688,984

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.